PubRank

N Wolmark

Author PubWeight™ 214.42‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998 22.10
2 Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998 9.32
3 Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med 1985 8.45
4 Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999 7.72
5 Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 1989 6.37
6 Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997 6.35
7 A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989 6.24
8 1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings. N Engl J Med 1975 5.48
9 Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med 1993 5.39
10 Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996 5.28
11 Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 1995 5.27
12 Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001 4.84
13 Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04) J Clin Oncol 1999 4.79
14 Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma. Cancer 1999 4.70
15 Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 1997 4.32
16 Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 1998 3.94
17 Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 1990 3.48
18 Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 1985 3.41
19 Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 2001 3.25
20 The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histologic nodal status in carcinoma of the breast. Surg Gynecol Obstet 1981 3.11
21 Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst 1988 3.09
22 Outcomes among African-Americans and Caucasians in colon cancer adjuvant therapy trials: findings from the National Surgical Adjuvant Breast and Bowel Project. J Natl Cancer Inst 1999 3.07
23 Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol 2001 3.00
24 Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990 2.91
25 erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998 2.85
26 Significance of ipsilateral breast tumour recurrence after lumpectomy. Lancet 1991 2.70
27 Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. J Natl Cancer Inst 2001 2.12
28 An analysis of survival and treatment failure following abdominoperineal and sphincter-saving resection in Dukes' B and C rectal carcinoma. A report of the NSABP clinical trials. National Surgical Adjuvant Breast and Bowel Project. Ann Surg 1986 2.06
29 Doxorubicin-containing regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol 1989 2.03
30 A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med 1989 1.99
31 Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol 1996 1.98
32 Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol 1983 1.94
33 The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994 1.94
34 Ten year follow-up results of patients with carcinoma of the breast in a co-operative clinical trial evaluating surgical adjuvant chemotherapy. Surg Gynecol Obstet 1975 1.91
35 Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 2001 1.87
36 HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 2000 1.85
37 Interstitial hypertension in human breast and colorectal tumors. Cancer Res 1992 1.67
38 A clinical trial to evaluate the worth of preoperative multimodality therapy in patients with operable carcinoma of the rectum: a progress report of National Surgical Breast and Bowel Project Protocol R-03. Dis Colon Rectum 1997 1.58
39 Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803. Eur J Cancer 2011 1.57
40 Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 1997 1.56
41 Thermal expansion measurements of frozen biological tissues at cryogenic temperatures. J Biomech Eng 1998 1.56
42 Tumor size and regional lymph node metastasis in colorectal cancer. A preliminary analysis from the NSABP clinical trials. Cancer 1983 1.51
43 Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med 1981 1.45
44 The prognostic value of the modifications of the Dukes' C class of colorectal cancer. An analysis of the NSABP clinical trials. Ann Surg 1986 1.41
45 Prolonging tamoxifen therapy for primary breast cancer. Findings from the National Surgical Adjuvant Breast and Bowel Project clinical trial. Ann Intern Med 1987 1.39
46 Fifteen-year prognostic discriminants for invasive breast carcinoma: National Surgical Adjuvant Breast and Bowel Project Protocol-06. Cancer 2001 1.37
47 Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Oncol 1999 1.36
48 The prognostic significance of tumor location and bowel obstruction in Dukes B and C colorectal cancer. Findings from the NSABP clinical trials. Ann Surg 1983 1.28
49 Observations following Corynebacterium parvum administration to patients with advanced malignancy. a phase I study. Cancer 1976 1.25
50 Geometric resistance and microvascular network architecture of human colorectal carcinoma. Microcirculation 1997 1.25
51 Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer. J Natl Cancer Inst Monogr 2001 1.24
52 The prognostic significance of preoperative carcinoembryonic antigen levels in colorectal cancer. Results from NSABP (National Surgical Adjuvant Breast and Bowel Project) clinical trials. Ann Surg 1984 1.22
53 Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial. J Clin Oncol 1986 1.17
54 Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Five-year observations concerning lobular carcinoma in situ. Cancer 1996 1.17
55 Findings from NSABP Protocol No. B-04: comparison of radical mastectomy with alternative treatments. II. The clinical and biologic significance of medial-central breast cancers. Cancer 1981 1.10
56 Cancer survivorship research: the challenge of recruiting adult long term cancer survivors from a cooperative clinical trials group. J Cancer Surviv 2009 1.04
57 The effect of a single and repeated administration of Corynebacterium parvum on bone marrow macrophage colony production in syngeneic tumor-bearing mice. Cancer Res 1974 1.03
58 The relationship of depth of penetration and tumor size to the number of positive nodes in Dukes C colorectal cancer. Cancer 1984 1.02
59 Distinctive patterns of Her-2/neu, c-myc, and cyclin D1 gene amplification by fluorescence in situ hybridization in primary human breast cancers. Cytometry 2001 1.01
60 Acute toxicity during adjuvant chemotherapy for breast cancer: the National Surgical Adjuvant Breast and Bowel Project (NSABP) experience from 1717 patients receiving single and multiple agents. Cancer Treat Rep 1981 1.01
61 The effect of a single and repeated administration of Corynebacterium parvum on bone marrow macrophage colony production in normal mice. J Reticuloendothel Soc 1974 1.00
62 Long-term tamoxifen citrate use and potential ocular toxicity. Am J Ophthalmol 1998 1.00
63 Dukes' classification revisited. Findings from the National Surgical Adjuvant Breast and Bowel Projects (Protocol R-01). Cancer 1989 0.99
64 A comparison of stapled and handsewn anastomoses in patients undergoing resection for Dukes' B and C colorectal cancer. An analysis of disease-free survival and survival from the NSABP prospective clinical trials. Dis Colon Rectum 1986 0.99
65 Correlations among p53, Her-2/neu, and ras overexpression and aneuploidy by multiparameter flow cytometry in human breast cancer: evidence for a common phenotypic evolutionary pattern in infiltrating ductal carcinomas. Clin Cancer Res 2000 0.98
66 Positional distribution of fatty acids in triglycerides of animal depot fats. Biochim Biophys Acta 1966 0.97
67 Systemic adjuvant therapy in treatment of primary operable breast cancer: National Surgical Adjuvant Breast and Bowel Project experience. NCI Monogr 1986 0.94
68 Sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer. Am J Surg 2001 0.93
69 Status of adjuvant therapy for colorectal cancer. J Natl Cancer Inst 1989 0.92
70 Inhibitory effect of prolonged Corynebacterium parvum and cyclophosphamide administration on the growth of established tumors. Cancer 1975 0.92
71 Lumpectomy and axillary dissection for breast cancer: surgical, pathological, and radiation considerations. World J Surg 1985 0.92
72 Gross damage accumulation on frozen rabbit liver due to mechanical stress at cryogenic temperatures. Cryobiology 1997 0.90
73 Further observations on the inhibition of tumor growth by Corynebacterium parvum with cyclophosphamide. I. Variation in administration of both agents. J Natl Cancer Inst 1975 0.87
74 Systemic therapy in patients with node-negative breast cancer. A commentary based on two National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trials. Ann Intern Med 1989 0.86
75 Evaluation of the worth of corynebacterium parvum in conjunction with chemotherapy as adjuvant treatment for primary breast cancer. Eight-year results from the National Surgical Adjuvant Breast and Bowel Project B-10. Cancer 1990 0.85
76 Disease-free survival at intervals during and following completion of adjuvant chemotherapy: the NSABP experience from three breast cancer protocols. Cancer 1981 0.84
77 Survival impact of chemotherapy in patients with colorectal metastases confined to the liver: a re-analysis of 1458 non-operable patients randomised in 22 trials and 4 meta-analyses. Meta-Analysis Group in Cancer. Ann Oncol 1999 0.83
78 A compact cryosurgical apparatus for minimally invasive procedures. Biomed Instrum Technol 1997 0.83
79 Early stopping of a clinical trial when there is evidence of no treatment benefit: protocol B-14 of the National Surgical Adjuvant Breast and Bowel Project. Control Clin Trials 1998 0.82
80 Delayed severe hypertriglyceridemia from tamoxifen. N Engl J Med 1997 0.81
81 Residence time distributions of various tracers in tumors: implications for drug delivery and blood flow measurement. J Natl Cancer Inst 1994 0.81
82 Preparation of viable tumour cell vaccine from human solid tumours: relationship between tumour mass and cell yield. The Tissue Bank, Pittsburgh Cancer Institute. Melanoma Res 1993 0.81
83 Long-term follow-up post-cryosurgery in a sheep breast model. Cryobiology 1999 0.81
84 An experimental study of the mechanical response of frozen biological tissues at cryogenic temperatures. Cryobiology 1996 0.81
85 New concepts in the management of primary breast cancer. Cancer 1975 0.79
86 Inflammatory cell infiltrate in a responding metastatic nodule after vaccine-based immunotherapy. Clin Exp Immunol 1998 0.78
87 Endogenous sex hormone levels and breast cancer risk. Genet Epidemiol 1987 0.78
88 Surgery in the primary treatment of breast cancer. Breast Cancer Res Treat 1981 0.78
89 Correlation of antitumor chemoimmunotherapy with bone marrow macrophage precursor cell stimulation and macrophage cytotoxicity. Cancer Res 1976 0.77
90 Preliminary observations on the use of Corynebacterium parvum in patients with primary intracranial tumors: effect on intracranial pressure. J Surg Oncol 1978 0.77
91 Further observations on the inhibition of tumor growth by Corynebacterium parvum with cyclophosphamide. III. Effect of C. parvum on cyclophosphamide metabolism. J Natl Cancer Inst 1976 0.77
92 Stapled Baker type anastomosis for low anterior resections. Surg Gynecol Obstet 1990 0.77
93 Non-invasive breast carcinoma. Breast Cancer Res Treat 1992 0.76
94 Adjuvant tamoxifen and chemotherapy in stage II breast cancer: interim findings from NSABP protocol B-09. World J Surg 1985 0.75
95 Adjuvant chemotherapy in stage II breast cancer: a brief overview of the NSABP clinical trials. World J Surg 1985 0.75
96 Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study. Breast Cancer Res Treat 2014 0.75
97 Limited surgical management for primary breast cancer: a commentary on the NSABP reports. World J Surg 1985 0.75
98 Laminated Marlex-methyl methacrylate prosthesis for massive chest wall resection. Ann Plast Surg 1980 0.75
99 Adjuvant chemotherapy in colorectal cancer. Can J Surg 1985 0.75
100 Further observations on the inhibition of tumor growth by corynebacterium parvum with cyclophosphamide. J Natl Cancer Inst 1976 0.75
101 Conservative surgery: the American experience. Semin Oncol 1986 0.75
102 Cellular cytotoxicity and serum inhibition in normal mice following transfer of syngeneic tumor-sensitized cells. J Natl Cancer Inst 1980 0.75
103 Studies concerning the regional lymph node in cancer. VIII. Effect of two asynchronous tumor foci on lymph node cell cytotoxicity. Cancer 1975 0.75
104 Adoptive immunotherapy of murine mammary carcinoma using broadly cytotoxic cloned T lymphocytes. Prog Clin Biol Res 1987 0.75
105 Future directions in the adjuvant treatment of colon cancer. Oncology (Williston Park) 1997 0.75
106 Effect of Corynebacterium parvum on cytotoxicity of regional and nonregional lymph node cells from animals with tumors present or removed. J Natl Cancer Inst 1974 0.75
107 Effect of prolonged Corynebacterium parvum and cyclophosphamide administration on spontaneously occurring metastases. Surg Forum 1975 0.75
108 Indications for breast-preserving surgery and adjuvant therapy in early breast cancer. Int Surg 1994 0.75
109 The effect of Corynebacterium parvum in combination with 5-fluorouracil, L-phenylalanine mustard, or methotrexate on the inhibition of tumor growth. Cancer Res 1976 0.75
110 Cellular cytotoxicity and serum inhibition in normal mice following transfer of xenogeneic tumor-sensitized cells. Cancer Res 1979 0.75
111 Improved lymphocyte cytotoxicity against murine renal cell carcinoma. J Urol 1992 0.75
112 The effect of a growing tumor and its removal on the cytotoxicity of macrophages from cultured bone marrow cells. Cancer Res 1976 0.75
113 Chemoimmunotherapy of metastatic murine renal cell carcinoma using flavone acetic acid and interleukin 2. J Urol 1992 0.75
114 The current status of systemic adjuvant therapy in the management of primary breast cancer. Surg Clin North Am 1981 0.75
115 Minimal breast cancer: advance or anachronism? Can J Surg 1985 0.75
116 Further observations on the inhibition of tumor growth by Corynebacterium parvum with cyclophosphamide. II. Effect of cortisone acetate. J Natl Cancer Inst 1976 0.75
117 Cellular cytotoxicity in tumor-bearing mice after transfer of normal or tumor-sensitized lymphoid cells. J Natl Cancer Inst 1980 0.75
118 Adjuvant therapy in primary breast cancer. Surg Clin North Am 1985 0.75
119 The triple-stapled colonic anastomosis. Dis Colon Rectum 1989 0.75
120 Adjuvant chemotherapy in stage-II breast cancer: an overview of the NSABP clinical trials. Breast Cancer Res Treat 1983 0.75